Regeneron Pharmaceuticals says Libtayo achieves 37% reduction in risk of death at 44 months (HR 0.63)
REGN•Regeneron Pharmaceuticals said Libtayo achieved a 37% reduction in risk of death at 44 months (HR 0.63) and confirmed a sustained disease-free survival benefit, including in MRD-negative patients.
1. Trial results
Regeneron Pharmaceuticals said Libtayo achieved a 37% reduction in risk of death at 44 months (HR 0.63). The company also said Libtayo confirmed a sustained disease-free survival benefit, including in MRD-negative patients.
